Table 2.
Levels of creatin kinase (CK) and lactate dehydrogenase (LDH) in serum and coronary venous effluent (CVE) under basal conditions and during reperfusion after global ischemia of different durations.
| Group (treatment) | Basal conditions (U/L in CVE) | 30 s ischemia (U/L in CVE) | 1 min ischemia (U/L in CVE) | 2 min ischemia (U/L in CVE) | Serum (U/L) |
|---|---|---|---|---|---|
| CK | |||||
| Control | 7.00 ± 0.96c, * | 6.33 ± 0.67 | 6.66 ± 0.41 | 7.00 ± 0.71 | 198 ± 21.55c, ** |
| Cisplatin | 12.20 ± 2.10a, * | 13.20 ± 2.92a, * | 11.70 ± 2.25a, * | 11.33 ± 2.27a, * | 374.4 ± 9.72a, ** |
| Cisplatin + NAC | 10.94 ± 1.39 | 9.33 ± 2.53 | 9.33 ± 2.48 | 10.00 ± 2.63 | 337 ± 25.70 |
| LDH | |||||
| Control | 2.33 ± 0.41c, * | 2.00 ± 0.27 | 3.33 ± 0.31 | 2.00 ± 0.27 | 223.00 ± 15.92c, * |
| Cisplatin | 4.00 ± 0.53a, * | 4.50 ± 1.01a, * | 4.17 ± 0.23a, * | 3.83 ± 0.80a, * | 491.00 ± 60.68a, ** |
| Cisplatin + NAC | 3.97 ± 0.64 | 3.00 ± 0.53 | 3.67 ± 0.82 | 3.33 ± 1.11 | 330.50 ± 17.12b, * |
Values are expressed as mean ± S.E.M. for eight animals.
a
Control vs. cisplatin.
b
Cisplatin vs. cisplatin + NAC.
c
Control vs. cisplatin + NAC.
*
p < 0.05.
**
p < 0.01.